Company / Cost of Revenue
Axsome Therapeutics, Inc. Cost of Revenue History
FY2022-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$5.2M
FY2022
5-year range
$5.2M / $5.2M
FY2022-FY2022
Trend
-
vs FY2021
Sector context
#75 of 85
Health Care
What the data says
Axsome Therapeutics, Inc.'s cost of revenue of $5M is lower than 88% of companies in the Health Care sector (FY2022).
Based on SEC 10-K filings.
$5M in FY2022.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 85This company $5.2M Sector average $2.0B
▼
-99.7% below sector average
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $5.2M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2022 · SEC 10-K · Updated Feb 28, 2026